Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nateglinide.

C J Dunn1, D Faulds

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|October 13, 2000
PubMed
Summary
This summary is machine-generated.

Nateglinide, a D-phenylalanine derivative, effectively lowers blood glucose by stimulating insulin release in patients with type 2 diabetes. It shows significant improvements in glycaemic control, both alone and in combination therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional differences in the reduction in cerebral FDG uptake induced by the ketogenic diet.

European journal of hybrid imaging·2022
Same author

Bisphosphonates: a review of their novel anti-inflammatory properties and potential for the treatment of rheumatoid arthritis.

IDrugs : the investigational drugs journal·2008
Same author

Recombinant Factor VIIa.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Study on spontaneous cerebrospinal fluid rhinorrhoea: its aetiology and management.

The Journal of laryngology and otology·2005
Same author

Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2004
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Nateglinide is a D-phenylalanine derivative targeting ATP-sensitive K+ channels in pancreatic beta-cells.
  • It stimulates glucose-dependent insulin release, impacting prandial glucose levels.

Purpose of the Study:

  • To evaluate the efficacy of nateglinide in improving glycaemic control in type 2 diabetes mellitus.
  • To assess the effects of nateglinide monotherapy and combination therapy with other antidiabetic agents.

Main Methods:

  • Randomized, double-blind, placebo-controlled clinical studies.
  • Administration of oral nateglinide (60-120 mg TID) alone or in combination with metformin or troglitazone.
  • Assessment of glycaemic control parameters over 16-24 weeks.

Related Experiment Videos

Main Results:

  • Nateglinide (120 mg TID) significantly improved glycaemic control compared to placebo.
  • Combination therapy with metformin or troglitazone demonstrated superior glycaemic improvement versus monotherapy.
  • Mild hypoglycemia was the most common adverse event (1.3%).

Conclusions:

  • Nateglinide is an effective agent for managing type 2 diabetes mellitus.
  • Combination therapy offers enhanced glycaemic control.
  • Nateglinide exhibits a favorable safety profile with minimal adverse events.